Skip to main content
. 2019 Nov 16;4(2):bvz008. doi: 10.1210/jendso/bvz008

Table 2.

Treatment efficacy

Received Therapy Sustained Pain Resolution
Subgroup No. of Cases/Total No. (%) No. of Cases/Total No. Received Therapy (%)
Drug
 Corticosteroids 42/58 (72.4%) 14/42 (33.33%)
Route of administration
 Intrathyroidal injectiona 5/42 (11.9%) 4/5 (80.0%)
 Oral 41/42 (97.6%) 12/41 (29.3%)
Dosage of oral prednisone
 < 25 mg/d 12/23 (52.2%) 6/12 (50.0%)
 25 to 40 mg/d 8/23 (34.8%) 2/8 (25.0%)
 > 40 mg/d 3/23 (13.0%) 0/3 (0.0%)
Duration for each episode, mo
 < 1 6/29 (20.7%) 3/6 (50.0%)
 1 to 3 13/29 (44.8%) 8/13 (61.5%)
 > 3 10/29 (34.5%) 1/10 (10.0%)
CRP level
 CRP elevated 13/17 (76.5%) 4/13 (30.8%)
 CRP within normal limit 4/17 (23.5%) 1/4 (25.0%)
ESR level
 ESR elevated 16/33 (48.5%) 8/16 (50.0%)
 ESR within normal limit 17/33 (51.5%) 5/17 (29.4%)
 NSAIDs 21/58 (36.2%) 4/21 (19.0%)
 Levothyroxineb 26/58 (44.8%) 9/26 (34.6%)
Surgeryc
 Total thyroidectomy 21/31 (67.7%) 21/21 (100%)
 Near total thyroidectomy 3/31 (9.7%) 2/3 (66.7%)
 Subtotal thyroidectomy 6/31 (19.4%) 3/6 (50.0%)
 Partial thyroidectomy 1/31 (3.2%) Unknown

This efficacy analysis shows patients who received treatment that yield sustained pain relief.

Abbreviations: CRP, C-reactive protein; ESR, erythrocyte sedimentation rate, NSAIDs, nonsteroidal anti-inflammatory drugs.

aFour cases had preceding treatment with oral corticosteroids.

bAdministration of levothyroxine in patients without hypothyroidism at the time of initial diagnosis.

cWith or without prior medical treatment.